Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis has confirmed reports of tumors in patients treated with Zolgensma, a gene therapy for spinal muscular atrophy. Multiple sources report nine total tumor cases, including two with a possible direct link to the therapy. The FDA is actively reviewing the safety of Zolgensma amid growing concerns from patient advocacy groups and healthcare providers. Regulatory scrutiny intensifies as investigators assess whether the viral vector used in the treatment may integrate into DNA and cause malignancies.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
- ✓ FDA is investigating tumor risk tied to Novartis gene therapy
- ✓ Two tumor cases may be directly linked to the gene therapy via viral vector DNA integration
- ✓ Patient advocacy groups are calling for transparency on Zolgensma safety data
What changed
Novartis has publicly acknowledged nine tumor cases in Zolgensma-treated patients, including two with a possible causal link, and the FDA has launched an investigation into the safety concerns.
Live updates
-
Novartis confirms tumor cases linked to Zolgensma, FDA investigating
Novartis has confirmed reports of tumors in patients treated with Zolgensma, a gene therapy for spinal muscular atrophy. Multiple sources report nine total tumor cases, including two with a possible direct link to the therapy. The FDA is actively reviewing the safety of Zolgensma amid growing concerns from patient advocacy groups and healthcare providers. Regulatory scrutiny intensifies as investigators assess whether the viral vector used in the treatment may integrate into DNA and cause malignancies.
Why it matters
Zolgensma, approved for infants with spinal muscular atrophy, uses a modified virus to deliver a functional copy of the SMN1 gene. The therapy costs approximately $2.1 million per dose and has been hailed as a breakthrough treatment. Concerns about tumor development emerged after early trials, where integration of the viral vector into the genome raised theoretical cancer risks. Patient groups and clinicians are now pushing for transparency and long-term safety data following these reports.
What is confirmed
- Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
- FDA is investigating tumor risk tied to Novartis gene therapy
- Two tumor cases may be directly linked to the gene therapy via viral vector DNA integration
- Patient advocacy groups are calling for transparency on Zolgensma safety data
Still unconfirmed
- Zolgensma caused tumors in two children via gene therapy vector integration
- The FDA label still calls the tumor risk theoretical despite confirmed cases
What to watch next
- FDA investigation findings and any safety label updates
- Additional tumor case reports from post-marketing surveillance
- Long-term follow-up data from clinical trials and patient registries
confidence 70%Sources used for this update (11)
- BioSpace — Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
- FirstWord Pharma — Novartis faces questions over tumours reported after Zolgensma treatment
- STAT — Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
- Reuters — FDA probes tumour risk tied to Novartis gene therapy
- Fierce Pharma — Novartis confirms more reported tumor cases in Zolgensma patients as SMA groups seek details
- SWI swissinfo.ch — Novartis reports cases of tumours in children following treatment with Zolgensma
- www.biospace.com — Novartis confirms 9 reported cases of tumors in patients ...
- www.techtimes.com — Novartis Confirms Zolgensma Caused Tumors in Two Children Via ...
- www.emjreviews.com — FDA investigates Novartis gene therapy link to tumours in children
- www.clinicalobserver.com — Novartis reports tumors in children given Zolgensma
- trial.medpath.com — Novartis Reports Seven Previously Unknown Tumor Cases in ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community